Absolutely. This cash will go along way to extending the runway prior to the next capital raise. The longer this runway is pushed out the greater the chance of SP undergoing a re rating in light of positive clinical data results - which naturally means less dilution for current shareholders.I have my fingers crossed for a positive result in the UTI treatment study this FY. Whilst sepsis might be a bigger fish - I feel that UTI will be a quicker path to commercialisation.
GLTA
Absolutely. This cash will go along way to extending the runway...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
-0.010(3.28%) |
Mkt cap ! $85.06M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.5¢ | 29.0¢ | $51.83K | 172.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 84029 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 13000 | 1 |
View Market Depth
| Last trade - 16.10pm 19/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |